AstraZeneca’s Boston BioHub is excited to announce the arrival of OLARIS, its most recent company to on-board as a life sciences incubator resident.
Moving to the Boston BioHub on October 1, 2019, OLARIS’s mission is to fundamentally change how diseases are diagnosed and treated. With a pioneering metabolomics platform and machine learning algorithms the company produces Biomarkers of Response (BoR) to readily differentiate drug Responders (R) from Non-Responders (NR). Their primary focus is metastatic breast cancer.
“OLARIS is incredibly honored and excited to join AstraZeneca’s BioHub community. From the moment you walk through the door, AstraZeneca’s passion for new technology and commitment to help patients radiates. This ecosystem of passion and innovation is the ideal atmosphere for OLARIS as we move closer to bring our biomarker technology to patients. The amazing and generous AstraZeneca team has not only welcomed us but has already provided new insights to aid us on our mission. We look forward to continue to learn, create and innovate together” said Elizabeth O’Day, OLARIS’s CEO and Founder.